STRATIFYHF: Artificial intelligence-based decision support system for risk stratification and early detection of heart failure in primary and secondary care

心力衰竭(HF)是一种流行病，目前在欧洲影响着多达1500万人。这是一种复杂的临床综合征，表现为心脏功能受损，并与患者的生活质量差和高昂的医疗费用有关。临床上对新型人工智能(AI)工具的需求很高，这些工具将有助于心衰的风险分层、早期诊断和疾病进展评估。这些工具对于迅速启动循证预防和治疗策略至关重要，这将提高患者的生活质量，降低发病率和死亡率，并减少医疗保健的心力衰竭负担。STRATIFYHF的目标是开发、验证和实施第一个基于人工智能的决策支持系统(DSS)，用于HF的风险分层、早期诊断和疾病进展评估，以满足初级和二级护理的临床需求。DSS将使用现有和新的技术整合患者特定的人口统计和临床数据，并建立基于人工智能的工具，使用机器学习进行风险分层和HF预测。此外，还将开发一款移动应用程序，使患者能够更好地管理自己的病情，并使医疗保健专业人员在选择循证的心力衰竭预防和治疗策略时做出明智的决定。我们的多学科联盟，包括三家中小型企业(SMEs)和两家利益相关者组织，将在医疗咨询以及监管和卫生技术专家的指导下，将DSS作为医疗2b级设备提供，在项目结束时达到TRL 8。STRATIFYHF将改变目前诊断心力衰竭的方式，从而改善患者的生命质量和寿命，并通过减少欧洲及其他地区与心力衰竭相关的住院和从初级到二级护理的不必要转诊数量，导致高效和可持续的医疗体系。

Heart failure (HF) is a pandemic currently affecting up to 15 million people in Europe. It is a complex clinical syndrome presenting with impaired heart function and is associated with poor quality of life for patients and high healthcare costs. There is a high clinical demand for novel artificial intelligence (AI) tools which will facilitate risk stratification, early diagnosis, and disease progression assessment in HF. Such tools are essential to allow prompt initiation of evidence-based prevention and treatment strategies which will improve patient quality of life, reduce morbidity and mortality and the HF burden on healthcare. STRATIFYHF aims to develop, validate and implement the first AI-based, decision support system (DSS) for risk stratification, early diagnosis, and disease progression assessment in HF to accommodate both primary and secondary care clinical needs. The DSS will integrate patient-specific demographic and clinical data using existing and novel technologies and establish AI-based tools for risk stratification and HF prediction using machine learning. Additionally, a mobile app will be developed to empower patients to better manage their condition, and health care professionals to make informed decision in selection of evidence-based HF prevention and treatment strategies. Our multidisciplinary consortium, including three small-to-medium enterprises(SMEs) and two stakeholder organisations, will be guided by medical advice and regulatory and health technology experts to deliver the DSS as a medical class 2b device, reaching TRL 8 by the end of the project. STRATIFYHF will change the way in which HF is diagnosed today and thereby improve the quality and length of patients’ lives and lead to efficient and sustainable healthcare systems by reducing the number of HF-related hospital admissions and unnecessary referrals from primary to secondary care in Europe and beyond.